晚期NSCLC吉非替尼治疗失败后的再次治疗(病例报告及文献复习)  

Gefitinib retreatment of advanced non-small cell lung cancer:A case report and literature review

作　　者：管莎[1] 章必成[1] 赵杰[1] 饶智国[1] 高建飞[1] 

机构地区：[1]广州军区武汉总医院肿瘤科,湖北武汉430070

出　　处：《现代肿瘤医学》2013年第6期1249-1251,共3页Journal of Modern Oncology

摘　　要：目的:对吉非替尼治疗失败后的晚期NSCLC患者再次使用吉非替尼治疗,分析其疗效及安全性。方法:复习1例吉非替尼治疗失败后的晚期NSCLC患者再次使用吉非替尼治疗及临床资料,结合相关文献探讨其临床特征、治疗及预后。结果:该患者首次使用吉非替尼约8月后耐药,停药5月后再次使用吉非替尼,1月后复查肺部CT提示肺部病灶明显缩小,2个月后再次失效,最终总生存期达21月,使用吉非替尼期间不良反应轻微。结论:曾使用吉非替尼有效的晚期NSCLC患者,再次使用吉非替尼仍有可能延长其生存时间且不良反应轻微。Objective：To evaluate the efficacy and toxicity of gefitinib retreatment of advanced non-small cell lung cancer.Methods：To review the treatment and follow-up data of an advanced non-small cell lung cancer patient who was retreated with gefitinib due to failure of the initial gefitinib therapy and investigate the pertinent liateratures.Results：The initial gefitinib therapy lasted about 8 months,and the patient was retreated with gefitinib after 5 months.The chest CT showed partial remission（PR） 1 month later and then disease progression after 2 months.The overall survival was 21 months.Mild toxicity was observed.Conclusion：Patients with NSCLC may still be expected to achieve prolonged survival through gefitinib retreatment if they initially responded to gefitinib and undergo mild toxicity.

关 键 词：NSCLC 吉非替尼 再次吉非替尼治疗 

分 类 号：R734.2[医药卫生—肿瘤]